A new study published in JAMA Network Open is adding fresh evidence to one of the most politically charged debates in American healthcare. Researchers found that transgender youth who were prescribed puberty blockers had significantly lower rates of diagnosed mood disorders and suicidal thoughts and behaviors than transgender youth who did not receive the treatment.
The nationwide retrospective cohort study analyzed insurance claims data from 231,783 young people between the ages of 10 and 17 from 2016 through 2025. Of those, more than 41,000 were identified as transgender through medical claims data. Researchers compared transgender and cisgender youth, both with and without prescriptions for puberty blockers, while adjusting for demographic, socioeconomic, and regional differences.
The findings underscore the stark mental health disparities facing transgender youth. Overall, transgender adolescents were more than four times as likely to receive a mood disorder diagnosis and more than 12 times as likely to receive a diagnosis related to suicidal thoughts or behaviors compared with their cisgender peers.
However, the study found an important difference among transgender youth who received puberty blockers. Within that group, researchers observed approximately a 48% reduction in the adjusted odds of a diagnosed mood disorder and an approximately 80% reduction in the adjusted odds of suicidal thoughts or behaviors compared with transgender youth who did not receive puberty blockers.
Lead authors cautioned that the research demonstrates an association rather than direct causation. Because the study relied on insurance claims, it could not account for important factors such as family acceptance, school support, bullying, counseling, or community environment that also influence mental health outcomes.
The findings arrive amid an ongoing political campaign against gender-affirming care. More than half of U.S. states have enacted restrictions on puberty blockers and other forms of gender-affirming medical care for minors in recent years, often arguing that evidence supporting these treatments is insufficient.
Ironically, puberty blockers themselves are not experimental medications. They have been used safely for decades to treat central precocious puberty in cisgender children before later being adapted for carefully evaluated transgender adolescents experiencing gender dysphoria. Major medical organizations, including the American Academy of Pediatrics, the Endocrine Society, the Pediatric Endocrine Society, and the World Professional Association for Transgender Health continue to support their use in appropriate clinical settings.
The researchers concluded that while puberty blockers did not eliminate the mental health gap between transgender and cisgender youth, they appeared to reduce it significantly. They also noted that persistent disparities likely reflect broader social factors, including discrimination, family rejection, and minority stress rather than medical treatment alone.
As lawmakers continue debating restrictions on gender-affirming healthcare, this study adds another large-scale dataset to a growing body of research suggesting that access to medically supervised puberty blockers is associated with improved mental health outcomes for transgender adolescents, even as researchers emphasize the need for continued long-term study.
